Wed, Apr 16, 2014, 2:25 PM EDT - U.S. Markets close in 1 hr 35 mins

Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

ustupit 3 posts  |  Last Activity: Apr 4, 2014 7:22 AM Member since: Apr 11, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ustupit by ustupit Apr 4, 2014 7:22 AM Flag

    It also has an intellectual property portfolio of 125 patents related to the visual display of digital image data. The company sells its products through a direct sales force, distributors, and manufacturers’ representatives worldwide.

  • Shares of Pixelworks, Inc. (PXLW) soared 87.5% ($4.20) to $9.00 on Mar 6, 2014, after it announced that Apple Inc. (AAPL) accounted for more than 10.0% of its revenues in 2013. Pixelworks earned revenues of $48.1 million in 2013.

    Pixelworks’ solutions are used for processing high-end digital video applications. Its technology solves judder and motion blur problem and also reduces halo effects on any screen. Pixelworks’ solutions help in converting low resolution content to high resolution display and also deliver high-quality mobile video on networked screens.

    Although it is not exactly clear what Pixelworks is supplying to Apple, the revelation has started a strong rumor-mill about the iPhone makers’ next innovative device. It is a well-known fact that Apple is developing wearable devices, which, according to its Chief Executive Officer (CEO) Tim Cook, is an interesting market.

    In an interview at All Things D's D11 Conference, CEO Cook had specified that Apple TV continues to hold great importance for the company. The growing relationship with Pixelworks suggests that Apple could use its technology in overhauling the long awaited iTV. Apple can also use it in building high-resolution screens for mobile and wearable devices.

    Nonetheless, we believe this is an important relationship for both Pixelworks and Apple. The association will not only drive Pixelworks’ top line but also improve its competitive position. We also believe that Pixelworks can be a prospective acquisition candidate for Apple.

    Apple has a habit of grabbing small companies and start-ups, whose technology boosts and extends its eco-system. In this regard, Shares of Pixelworks, Inc. (PXLW) soared 87.5% ($4.20) to $9.00 on Mar 6, 2014, after it announced that Apple Inc. (AAPL) accounted for more than 10.0% of its revenues in 2013. Pixelworks earned revenues of $48.1 million in 2013.

    Pixelworks’ solutions are used for processing high-end digital video applications. Its technology solves judder and motion blur problem and also reduces halo effects on any screen. Pixelworks’ solutions help in converting low resolution content to high resolution display and also deliver high-quality mobile video on networked screens.

    Although it is not exactly clear what Pixelworks is supplying to Apple, the revelation has started a strong rumor-mill about the iPhone makers’ next innovative device. It is a well-known fact that Apple is developing wearable devices, which, according to its Chief Executive Officer (CEO) Tim Cook, is an interesting market.

    In an interview at All Things D's D11 Conference, CEO Cook had specified that Apple TV continues to hold great importance for the company. The growing relationship with Pixelworks suggests that Apple could use its technology in overhauling the long awaited iTV. Apple can also use it in building high-resolution screens for mobile and wearable devices.

    Nonetheless, we believe this is an important relationship for both Pixelworks and Apple. The association will not only drive Pixelworks’ top line but also improve its competitive position. We also believe that Pixelworks can be a prospective acquisition candidate for Apple.

    Apple has a habit of grabbing small companies and start-ups, whose technology boosts and extends its eco-system. In this regard,

  • ustupit by ustupit Feb 19, 2014 6:14 PM Flag

    which advanced 24.4% after receiving approval for Northera from the Food and Drug Administration for the treatment of low blood pressure and dizziness in Parkinson's disease patients. The FDA panel's overwhelming recommendation for approval, and today's FDA approval, are still a bit of a shock because the drug seems to be quite effective over the short term (a few weeks), but it hasn't demonstrated the type of long-term effectiveness that I would have expected to see with an FDA approval. Peak sales estimates of the drug are approximately $400 million, so there's certainly room for Chelsea to run higher. The question will be whether or not it can effectively launch its new product.

MDXG
5.82+0.09(+1.57%)2:23 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.